Using this concept, we have succeeded in extracting from the same source of material (ClairYg®,a commercial IVIg preparation) 4 candidate products (anti-RSV supposedly from symptom-free to mild cold in healthy immunocompetent adults, anti-tetanus and anti-hepatitis B hyper enriched Igs from vaccinated adults and one fraction which could be used in the treatment of AIDs). Here, CUBN is linked to tetanus.